Advertisement
Advertisement
AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock
13.20
USDSponsored
-0.52
-3.79%
May 08, 15:59 UTC -4
Closed
After-Market
13.18
-0.02
-0.19%
AMRX Earnings Reports
Positive Surprise Ratio
AMRX beat 28 of 42 last estimates.
67%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$772.37M
/$0.23
Implied change from Q1 26 (Revenue/ EPS)
+6.90%
/-14.81%
Implied change from Q2 25 (Revenue/ EPS)
+6.61%
/-8.00%
Amneal Pharmaceuticals, Inc. Class A Common Stock earnings per share and revenue
On Apr 22, 2026, AMRX reported earnings of 0.27 USD per share (EPS) for Q1 26, beating the estimate of 0.17 USD, resulting in a 55.71% surprise. Revenue reached 722.52 million, compared to an expected 729.58 million, with a -0.97% difference. The market reacted with a -1.54% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of 0.23 USD, with revenue projected to reach 772.37 million USD, implying an decrease of -14.81% EPS, and increase of 6.90% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
NewAmsterdam Pharma Company N.V. Ordinary Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.40
Surprise
+20.32%
ZOETIS INC.
Report Date
May 07, 2026 For Q1 26
Estimate
$1.63
Actual
$1.53
Surprise
-6.19%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
Xeris Biopharma Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+296.08%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
May 07, 2026 For Q1 26
Estimate
$0.24
Actual
$0.24
Surprise
-1.96%
SIGA Technologies Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Profound Medical Corp. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.19
Surprise
+25.75%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
FAQ
What were Amneal Pharmaceuticals, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Amneal Pharmaceuticals, Inc. Class A Common Stock reported EPS of $0.27, beating estimates by 55.71%, and revenue of $722.52M, -0.97% below expectations.
How did the market react to Amneal Pharmaceuticals, Inc. Class A Common Stock's Q1 2026 earnings?
The stock price moved down -1.54%, changed from $13.02 before the earnings release to $12.82 the day after.
When is Amneal Pharmaceuticals, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Amneal Pharmaceuticals, Inc. Class A Common Stock's next earnings report?
Based on 6
analysts, Amneal Pharmaceuticals, Inc. Class A Common Stock is expected to report EPS of $0.23 and revenue of $772.37M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement